Nothing Special   »   [go: up one dir, main page]

RS55641B1 - Dijagnostičko sredstvo interferon tipa 1 - Google Patents

Dijagnostičko sredstvo interferon tipa 1

Info

Publication number
RS55641B1
RS55641B1 RS20170089A RSP20170089A RS55641B1 RS 55641 B1 RS55641 B1 RS 55641B1 RS 20170089 A RS20170089 A RS 20170089A RS P20170089 A RSP20170089 A RS P20170089A RS 55641 B1 RS55641 B1 RS 55641B1
Authority
RS
Serbia
Prior art keywords
interferon
diagnostic
type
interferon diagnostic
Prior art date
Application number
RS20170089A
Other languages
English (en)
Inventor
Brandon Higgs
Wei Zhu
Chris Morehouse
Barbara White
Bahija Jallal
Yihong Yao
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of RS55641B1 publication Critical patent/RS55641B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20170089A 2009-09-03 2010-09-02 Dijagnostičko sredstvo interferon tipa 1 RS55641B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23963009P 2009-09-03 2009-09-03
PCT/US2010/047721 WO2011028933A1 (en) 2009-09-03 2010-09-02 Type 1 interferon diagnostic

Publications (1)

Publication Number Publication Date
RS55641B1 true RS55641B1 (sr) 2017-06-30

Family

ID=43649646

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170089A RS55641B1 (sr) 2009-09-03 2010-09-02 Dijagnostičko sredstvo interferon tipa 1

Country Status (23)

Country Link
US (3) US20120251546A1 (sr)
EP (1) EP2473636B1 (sr)
JP (2) JP5727484B2 (sr)
KR (1) KR20120101340A (sr)
CN (1) CN102753704A (sr)
AU (1) AU2010289383B2 (sr)
BR (1) BR112012004781A2 (sr)
CA (1) CA2772921A1 (sr)
CY (1) CY1118566T1 (sr)
DK (1) DK2473636T3 (sr)
ES (1) ES2613055T3 (sr)
HR (1) HRP20170091T1 (sr)
HU (1) HUE032917T2 (sr)
LT (1) LT2473636T (sr)
ME (1) ME02599B (sr)
MX (1) MX2012002640A (sr)
PL (1) PL2473636T3 (sr)
PT (1) PT2473636T (sr)
RS (1) RS55641B1 (sr)
RU (1) RU2012112802A (sr)
SI (1) SI2473636T1 (sr)
SM (1) SMT201700063B (sr)
WO (1) WO2011028933A1 (sr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1552021A4 (en) * 2002-06-11 2006-06-14 Idaho Res Foundation INTERFERON TYPE I INDUCIBLE PROTEINS FOR THE DETECTION OF VIRUS INFECTION
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
AU2008247398B2 (en) * 2007-05-03 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
JP6211513B2 (ja) * 2011-04-26 2017-10-11 ジェネンテック, インコーポレイテッド 自己免疫疾患の治療のための組成物及び方法
WO2013101771A2 (en) * 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
KR102320059B1 (ko) 2012-06-13 2021-11-01 아스트라제네카 아베 항-i형 인터페론 수용체(ifnar) 항체에 대한 고정 투여 계획
JP6531306B2 (ja) * 2015-02-20 2019-06-19 一三 西野 炎症性筋疾患鑑別マーカー及びそれを用いた炎症性筋疾患と非炎症性筋疾患の鑑別方法
CN105316404B (zh) * 2015-02-27 2017-02-22 中南大学湘雅二医院 系统性红斑狼疮生物标志物及其诊断试剂盒
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
CN105567861B (zh) * 2016-03-16 2018-12-14 宫蕊 Ifi27作为冠心病诊断标志物的用途
CN113508138B (zh) * 2019-02-15 2024-08-09 阿斯利康(瑞典)有限公司 I型干扰素介导的障碍
IL292706A (en) 2019-11-11 2022-07-01 Astrazeneca Ab Inhibition of type i interferon in systemic lupus erythematosus
CN115667309A (zh) 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
IL302871A (en) 2020-11-18 2023-07-01 Astrazeneca Ab Saving steroids
IL307748A (en) 2021-04-23 2023-12-01 Astrazeneca Ab ANTI-IFNAR1 dosage regimen for subcutaneous injection
WO2022223771A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
WO2022223770A1 (en) 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
WO2022235758A1 (en) * 2021-05-04 2022-11-10 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
AU2022274306A1 (en) 2021-05-12 2023-11-23 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
EP4412641A2 (en) 2021-10-04 2024-08-14 Astrazeneca AB Treatment of lupus
WO2024056631A1 (en) 2022-09-14 2024-03-21 Idorsia Pharmaceuticals Ltd S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases
WO2024079241A1 (en) 2022-10-13 2024-04-18 Astrazeneca Ab Treatment of lupus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500864A (ja) 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US7247425B2 (en) * 1998-01-30 2007-07-24 Evolutionary Genomics, Llc Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
JP2008500009A (ja) * 2003-03-03 2008-01-10 ジェネンテック・インコーポレーテッド 全身性エリテマトーデスの治療のための組成物と方法
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
ES2368737T3 (es) 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
CN102344491B (zh) 2003-12-10 2015-03-11 梅达雷克斯有限责任公司 干扰素α抗体及其用途
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF PATIENTS OF BREAST CANCER USING A COMBINATION OF CLINICAL CRITERIA AND GENETIC INFORMATIVE SETS
CN102603894B (zh) 2004-06-21 2015-09-30 梅达雷克斯有限责任公司 干扰素α受体1抗体及其用途
PL2327792T3 (pl) * 2005-08-05 2014-03-31 Genentech Inc Sposoby i kompozycje do wykrywania zaburzeń autoimmunologicznych
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
WO2008016356A2 (en) * 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
EP2077858A4 (en) * 2006-12-06 2011-07-20 Medimmune Llc INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS
AU2008247398B2 (en) * 2007-05-03 2013-10-10 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
MX2010008698A (es) * 2008-02-08 2010-12-20 Medimmune Llc Marcadores de enfermedad y usos de los mismos.
WO2009130176A1 (en) * 2008-04-21 2009-10-29 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antiviral Therapy
WO2009149319A2 (en) * 2008-06-05 2009-12-10 Wyeth Gene expression profiles associated with asthma exacerbation attacks

Also Published As

Publication number Publication date
WO2011028933A1 (en) 2011-03-10
HRP20170091T1 (hr) 2017-03-24
US20120251546A1 (en) 2012-10-04
RU2012112802A (ru) 2013-10-10
SI2473636T1 (sl) 2017-04-26
HUE032917T2 (hu) 2017-11-28
CY1118566T1 (el) 2017-07-12
US20160024205A1 (en) 2016-01-28
EP2473636B1 (en) 2016-10-26
EP2473636A1 (en) 2012-07-11
ME02599B (me) 2017-06-20
JP2015147788A (ja) 2015-08-20
US20150191788A1 (en) 2015-07-09
LT2473636T (lt) 2017-02-10
PL2473636T3 (pl) 2017-05-31
PT2473636T (pt) 2017-02-06
KR20120101340A (ko) 2012-09-13
DK2473636T3 (en) 2017-02-06
AU2010289383A1 (en) 2012-04-19
SMT201700063B (it) 2017-03-08
ES2613055T3 (es) 2017-05-22
CN102753704A (zh) 2012-10-24
JP2013503642A (ja) 2013-02-04
BR112012004781A2 (pt) 2017-02-14
CA2772921A1 (en) 2011-03-10
EP2473636A4 (en) 2013-02-27
MX2012002640A (es) 2012-06-25
AU2010289383B2 (en) 2015-04-16
JP5727484B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
EP2473636A4 (en) INTERFERON DIAGNOSIS TYPE 1
GB0913345D0 (en) New combination 802
EP2513131A4 (en) NOVEL 3'-DEOXY-3'-METHYLIDENE-L-NUCLEOSIDES
GB0903160D0 (en) Fusebox 4
GB0916350D0 (en) Flexi-bend 2000
GB0921324D0 (en) Guttergrow 2
GB0901941D0 (en) 1007
GB0902804D0 (en) Fusebox 2
GB0900055D0 (en) Concept 46
GB0911960D0 (en) Concept 47
GB0911961D0 (en) Concept 48
GB0913052D0 (en) Concept 46
GB0916446D0 (en) Concept 21
GB0916447D0 (en) Concept 22
GB0916448D0 (en) Concept 23
GB0916449D0 (en) Concept 30
GB0916450D0 (en) Concept 29
GB0916451D0 (en) Concept 31
GB0916452D0 (en) Concept 32
GB0916453D0 (en) Concept 33
GB0916455D0 (en) Concept 34
GB0916456D0 (en) Concept 35
GB0916457D0 (en) Concept 36
GB0916460D0 (en) Concept 37
GB0916461D0 (en) Concept 38